Evaluation of Antimicrobial Use and Prescribing Patterns during the COVID-19 Pandemic in Patients Receiving Tocilizumab
Open Forum Infectious Diseases
; 8(SUPPL 1):S274-S275, 2021.
Article
in English
| EMBASE | ID: covidwho-1746653
ABSTRACT
Background. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients experience systemic inflammation and respiratory distress, which appears to be associated with increased cytokine release. During the peak of coronavirus disease 2019 (COVID-19), tocilizumab was used to treat critically ill patients with potential cytokine storm. However, tocilizumab has an increased risk of developing serious infections. Methods. This retrospective observational chart review was approved by Institutional Review Board and evaluated patients admitted from March to November 2020, who were SARS-CoV-2 positive and received tocilizumab for the treatment group and no tocilizumab for the control group. The primary endpoint is usage of antimicrobials. The secondary endpoints are development and outcomes of secondary infections and hospital length of stay and mortality. Chi-square test was used for categorical data and Mann-Whitney test was used for continuous data. Results. A total of 160 patients were included in analysis, with 80 in each arm. 60% of patients in the treatment group required antibiotics compared to 35% in the control group (p = 0.0015), with the highest usage of anti-MRSA coverage, betalactams, cephalosporins, and carbapenems in both groups. Antifungal therapy was required in 21.3% of patients in the tocilizumab group compared to 6.3% in the control group (p = 0.0059), with echinocandins being the most used class in both groups. The median days of antimicrobial use in the tocilizumab group was 14 (IQR 7, 24.5) compared to 9 (IQR 6.5, 19) in the control group (p = 0.3346). In the treatment group, 60% of patients developed a secondary infection compared to 35% of patients in the control group (p < 0.0017). Secondary infection treatment failure was observed in 75% of tocilizumab patients compared to 60.7% of control patients (p = 0.1910). In hospital mortality was 50% in patients who received tocilizumab compared to 27.5% in the control group (p < 0.0039). Conclusion. Patients on tocilizumab received more antimicrobials, but with a similar spectrum of antimicrobial coverage. Patients who received tocilizumab had higher odds of developing secondary infections and expiring during their hospital stay. There were similar durations of antimicrobial therapy and treatment outcomes.
antibiotic agent; antiinfective agent; beta lactam; carbapenem derivative; cephalosporin derivative; echinocandin; tocilizumab; adult; adverse drug reaction; antifungal therapy; clinical evaluation; conference abstract; controlled study; coronavirus disease 2019; critically ill patient; cytokine storm; drug therapy; female; hospitalization; human; in-hospital mortality; institutional review; length of stay; major clinical study; male; medical record review; methicillin resistant Staphylococcus aureus; mortality; nonhuman; outcome assessment; pandemic; prescribing practice; rank sum test; retrospective study; secondary infection; Severe acute respiratory syndrome coronavirus 2; side effect; treatment failure
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
Language:
English
Journal:
Open Forum Infectious Diseases
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS